Neuronetics (STIM) to Release Earnings on Tuesday

Key Points

• Neuronetics is expected to report its Q2 2025 earnings on August 5th, with analysts predicting earnings of ($0.08) per share and revenue of $36.80 million.
• The company's stock recently dropped 0.8%, with a trading price of $4.49, while it has a market cap of $296.50 million.
• Goldman Sachs Group Inc. significantly increased its stake in Neuronetics by 2,993.3% in the first quarter, owning about 0.96% of the company post-investment.

Neuronetics (NASDAQ:STIM - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Neuronetics to post earnings of ($0.08) per share and revenue of $36.80 million for the quarter. Neuronetics has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Neuronetics (NASDAQ:STIM - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.08). Neuronetics had a negative return on equity of 174.15% and a negative net margin of 53.67%. The company had revenue of $31.98 million for the quarter, compared to the consensus estimate of $29.07 million. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Stock Performance

STIM stock traded down $0.05 during midday trading on Friday, reaching $4.34. 184,962 shares of the company were exchanged, compared to its average volume of 1,171,089. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.44 and a quick ratio of 2.28. The business has a 50-day moving average price of $3.78 and a two-hundred day moving average price of $3.91. Neuronetics has a one year low of $0.52 and a one year high of $5.92. The firm has a market capitalization of $286.79 million, a price-to-earnings ratio of -3.32 and a beta of 1.85.

Insider Buying and Selling

In other news, EVP Stephen Furlong sold 193,460 shares of the business's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $4.27, for a total value of $826,074.20. Following the completion of the sale, the executive vice president owned 416,593 shares of the company's stock, valued at approximately $1,778,852.11. The trade was a 31.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Neuronetics

An institutional investor recently raised its position in Neuronetics stock. Goldman Sachs Group Inc. grew its holdings in Neuronetics, Inc. (NASDAQ:STIM - Free Report) by 2,993.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 630,393 shares of the company's stock after acquiring an additional 610,014 shares during the quarter. Goldman Sachs Group Inc. owned 0.96% of Neuronetics worth $2,320,000 as of its most recent SEC filing. 53.59% of the stock is currently owned by hedge funds and other institutional investors.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.